Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245412 · ClinicalTrials.gov registry record · Phase 2
A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02245412 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT02245412, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The objectives of this trial were to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in participants with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (GI) tract.
Interventions
- BIOLOGICAL ALXN1007 10 mg/kg once weekly
- BIOLOGICAL ALXN1007 20 mg/kg once weekly
- BIOLOGICAL ALXN1007 20 mg/kg twice weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-11-14 |
| Est. Completion | 2017-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245412
The ClinicalTrials.gov registry entry for NCT02245412 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ALXN1007 10 mg/kg once weekly is the first listed.
NCT02245412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02245412 about?
NCT02245412 is a clinical study titled "A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease". The objectives of this trial were to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in participants with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (GI) tract.
What is the current status of trial NCT02245412?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2014-11-14. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT02245412?
The interventions under investigation include: ALXN1007 10 mg/kg once weekly (BIOLOGICAL), ALXN1007 20 mg/kg once weekly (BIOLOGICAL), ALXN1007 20 mg/kg twice weekly (BIOLOGICAL).
Who is sponsoring clinical trial NCT02245412?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.